Maze shares jump after Vertex kidney drug study results
Maze Therapeutics shares rose after Vertex reported positive study results for its kidney disease drug, implying strong commercial potential for genetic kidney disease treatments.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.